Artic Study: Bedside Platelet Function Monitoring to Reduce Events after DES Implantation .

Given the individual variability of response to antiplatelet therapies, measuring platelet function and designing tailored therapies could be beneficial.

The ARTIC study tested the superiority of bedside platelet function monitoring with drug adjustment vs. the conventional post DES therapy without monitoring and drug adjustment. It included 2466 patients with stable coronary disease or Non-ST Elevation AMI. Platelet function was tested before angioplasty (PCI) and again 2-4 weeks later.

On the basis of identified resistance, high platelet reactivity to aspirin (AAS) led to the administration of an additional 500 mg bolus before PCI. After two weeks, when reactivity persisted, maintenance dose was doubled. High platelet reactivity to clopidogrel led to an additional loading 600 mg dose, or IIbIIIa glycoprotein inhibitors, or prasugrel administration. When resistant after two weeks, dose was doubled or switched to prasugrel.

Primary end point was a composite of death, infarction, stent thrombosis, urgent revascularization and stroke. After a year follow up, no differences were observed in the composite end point or in each individual component when comparing adjusted therapy vs. standard therapy (34,6% vs. 31,1% p=0,096 respectively). Bleeding events did not differ significantly between the two groups (3,1% vs 4,5% p=0,08 respectively).

Conclusion: According to the ARTIC trial, there is not enough evidence to support bedside platelet function monitoring.

Comment: though physiologically interesting, bedside platelet function monitoring has not shown clinical benefits in this trial, or in previous ones. Clopidogrel reactivity as a risk factor and event predictor seems not to be adjustable. 

1_gilles_montalescot
Gilles Montalescot
2012-11-04

Original title: A Randomized Trial of Bedside Platelet Function Monitoring to Adjust Antiplatelet Therapy Versus Standard of Care in Patients Undergoing Drug Eluting Stent Implantation. The Artic Study.

More articles by this author

TACT trial: Chelation Therapy for the Treatment of Coronary Disease.

In theory, also as for certain diseases caused by mineral deposits, Chelation treatment with EDTA (Ethylene Diamine Tetra-Acetic Acid) could reduce calcium and cholesterol...

TRILOGY Trial: First large scale test evaluating platelet function in acute coronary syndromes.

TRILOGY ACS which was presented at the ESC 2012 is a randomized, double blind study that included 10,300 patients and compared aspirin + cloplidogrel...

FREEDOM trial: CABG versus angioplasty treatment for diabetic patients with multivessel disease

The trial included 1,900 patients followed for at least 2 years, (mean 3.8 years), randomized 1:1 to pharmacological angioplasty stents, (sirolimus or paclitaxel at...

CPORT-E: Comparison of percutaneous treatment cost in hospitals with and without central vascular surgery.

A total of 18,273 patients receiving angioplasty in hospitals with or without central vascular surgery were followed for 9 months and the costs were...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of Fallot or other pathologies involving the right...

Radial Patency in Coronary Procedures: Is Heparin Enough or Should We Aim for Distal Transradial Access?

Transradial access is the preferred route in most coronary procedures due to its proven reduction in mortality compared to transfemoral access. However, one of...